# US 2005/0090646 A1 · Gene delivery to tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0090646 A1
- Document ID: US20050090646A1
- Status: Published application
- Kind: A1
- Application number: 10/864,774
- Filed: 2004-06-09
- Published: 2005-04-28
- Earliest claimed: 2003-06-09
- Assignees: University of Florida Research Foundation, Inc.
- Inventors: Sean Sullivan
- Web page: https://patentgrep.com/patent/US20050090646A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 14/43581: {from Drosophila}
- C07K 2319/02: containing a signal sequence
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are methods and compositions for gene therapy for tumors. Cytotoxic agents are selectively expressed in endothelial cells of tumor blood vessels, and delivered to tumor cells adjacent to the blood vessels, producing a bystander effect such that all the cells in contact with the transfected cells are killed or permanently growth arrested. In particular, cytotoxic gene products secreted from the transfected cell using a secretory signal sequence, include a membrane permeability domain at the N- or C-terminus that can shuttle the cytotoxic domain into non-transfected cells and back into transfected cells.

## Claims

### Claim 1

An isolated cytotoxic fusion protein comprising a membrane permeability domain and a cell toxicity domain.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the membrane permeability domain comprises a Tat peptide, synthetic peptide PTD-5 and/or Antenapedia homeodomain (ANT).

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the membrane permeability domain comprises the amino acid sequences identified by SEQ ID NO's: 1-2, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 4 (depends on 3)

The fusion protein of claim 3, wherein the membrane permeability domains are about 45% homologous to any one of SEQ ID NO's 1-2, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 5 (depends on 3)

The fusion protein of claim 3, wherein the membrane permeability domains are about 65% homologous to any one of SEQ ID NO's 1-2, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 6 (depends on 3)

The fusion protein of claim 3, wherein the membrane permeability domains are about 85% homologous to any one of SEQ ID NO's 1-2, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 7 (depends on 3)

The fusion protein of claim 3, wherein the membrane permeability domains are up to 99.9% homologous to any one of SEQ ID NO's 1-2, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

### Claim 8 (depends on 1)

The fusion protein of claim 1, wherein the cell toxicity domain comprises a cyclin kinase inhibitor peptide.

### Claim 9 (depends on 1)

The fusion protein of claim 1, wherein the cell toxicity domain comprises p16, p14, p19 peptides fragments or variants thereof.

### Claim 10 (depends on 1)

The fusion protein of claim 1, wherein the membrane permeability domain comprises any one of the sequences identified by SEQ ID NO's 1-2, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10 and a cell toxicity domain comprising a cyclin kinase inhibitor peptide, variants, fragments and/or combinations thereof.

### Claim 11 (depends on 10)

The fusion protein of claim 10, wherein the cyclin kinase inhibitor peptide is p14, p16, p19 variants or fragments thereof.

### Claim 12 (depends on 1)

The fusion protein of claim 1, further comprising a signal sequence.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

An expression vector comprising a nucleic acid encoding the fusion protein according to any one of claims 1-12.

### Claim 14 (depends on 13)

The vector of claim 13, further comprising a promoter that selectively drives expression of the fusion protein in endothelial cells.

### Claim 15 (depends on 14)

The vector of claim 14, further comprising a promoter that selectively drives expression of the fusion protein in proliferating cells.

### Claim 16 (depends on 15)

The vector of claim 15, wherein the promoter is 4×ETe/cdc6.

### Claim 17 (depends on 13)

An endothelial cell comprising the vector of claim 13.

### Claim 18 (depends on 17)

An endothelial cell comprising the vector of claim 17, further comprising a nucleic acid encoding a cytotoxic fusion protein that is secreted from the cell.

### Claim 19 (depends on 18)

The endothelial cell of claim 18, wherein the cell is within a blood vessel of a tumor, and said fusion protein is secreted from the endothelial cell and enters a tumor cell.

### Claim 20 (depends on 1)

A method of killing a cell comprising the step of contacting the cell with the cytotoxic fusion protein of claim 1.

### Claim 22 (depends on 20)

The method of claim 20, wherein the cell is a tumor cell.

### Claim 23 (depends on 20)

The method of claim 20, wherein the cell is an endothelial cell.

### Claim 24 (depends on 23)

The method of claim 23, wherein the endothelial cell is proliferating.

### Claim 25 (depends on 1)

A method of killing a cell comprising the steps of:
(a) providing a cell and;
(b) transfecting the cell with a vector comprising a nucleic acid encoding the fusion protein according to claim 1.

### Claim 26 (depends on 1)

A method of killing a tumor cell in a subject comprising the steps of:
(a) providing a subject having a tumor comprising at least one tumor cell; and
(b) contacting the tumor cell with the cytotoxic fusion protein of claim 1.

### Claim 27 (depends on 25)

The method of claim 25, wherein the encoded cytotoxic fusion protein is secreted basolaterally from the endothelium into the interstitium.

### Claim 28 (depends on 27)

The method of claim 27, wherein the secreted cytotoxic fusion protein is cytotoxic for tumor cells.

### Claim 29 (depends on 28)

The method of claim 28, wherein the tumor cell is a brain tumor.
